GammaDelta is developing the potential of gamma delta (γδ) T cells to create improved immunotherapy of cancer and other serious diseases. Based on the pioneering research of Professor Adrian Hayday at King’s College London and the Francis Crick Institute, the company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy. Takeda has formed a strategic collaboration with GammaDelta and, together with Abingworth, has committed up to $100 million in funding and has an exclusive option to acquire the company for an undisclosed sum.